NDAOPHTHALMICSUSPENSION/DROPS
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETOPTIC S (betaxolol hydrochloride) is a cardioselective beta-1 adrenergic receptor blocking agent administered as an ophthalmic suspension for reducing intraocular pressure in ocular hypertension and chronic open-angle glaucoma. It works by blocking beta-1 receptors in the eye to decrease aqueous humor production, with minimal systemic cardiovascular or pulmonary effects compared to non-selective beta-blockers like timolol.
$0.675MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Medicare spending signals declining team size and focus shifting to managed care/generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Started Jan 2019
366 enrolled
Primary Open-angle GlaucomaOcular Hypertension
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
Started Jan 2003
105 enrolled
GlaucomaOcular Hypertension
Career Relevance
BETOPTIC S offers limited career momentum given its approaching LOE status and modest market spending ($675K Part D). Roles supporting this product are typically operational/maintenance-focused rather than strategic growth opportunities.
Worked on BETOPTIC S at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.